Day: September 25, 2023

  Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia AALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment to delivering innovation and a paradigm shift in the hemophilia treatment landscapeParis, September 25, 2023. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for control of bleeding tendency in patients with hemophilia A (factor VIII deficiency). ALTUVIIIO was also recently approved by the Taiwan Food and Drug Administration for...

Ageas completes the sale of its French Life Insurance activities Ageas announces today that all regulatory approvals regarding the sale of its French life insurance, savings and pension business to La Mutuelle Epargne Retraite Prévoyance Carac (“Carac”) have been obtained and that the transaction has been completed. Ageas’s French Life and Pension activities consist of Ageas France, Ageas Retraite, Ageas Patrimoine and Sicavonline.Carac is a mutual operating in the domain of savings, protection and pension business in France. The operation will increase the liquidity of the Group by approximately EUR 185 million, and positively impact the Group’s Solvency II Pillar II ratio by 9% based on the position as at the end of June 2023.    Ageas is a listed international insurance Group with a heritage spanning almost 200 years. It offers Retail...

Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Deliveries will commence immediately. Dipal Patel, Chief Commercial Officer of Valneva commented, “We are excited to continue our long-term relationship with the DoD. The U.S. military has trusted IXIARO® for over ten years to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially...

Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a first line setting1Findings to be presented at an upcoming medical meeting and discussed with regulatory authorities, with submissions to followNovartis is investigating a broad portfolio of RLTs, exploring their treatment potential in a range of advanced cancers beyond prostate and GEP-NET, including lung, breast, pancreatic and colon. The company...